Combination Treatment for Melanoma Spread to Liver
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of liver-directed chemotherapy (HEPZATO KIT) with a new immunotherapy called Opdualag for people whose melanoma has spread to the liver and who have not had many prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have melanoma that has spread to your liver (confirmed by biopsy).
- You have had 0 or 1 prior treatment for advanced melanoma (including immunotherapy or targeted pills).
- Your weight is at least 35 kilograms (about 77 pounds).
- Your organs are working well based on blood tests done in the last month.
- You have not taken HEPZATO KIT or Opdualag before.
- You do not have uncontrolled brain metastases or require high-dose steroids.
- You have not had an organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a liver-directed therapy (PHP) to a combination of two immunotherapy drugs (ipilimumab and nivolumab) works better than the immunotherapy drugs alone for people whose uveal melanoma has spread to the liver.
This study tests a combination of two immunotherapy drugs (nivolumab and relatlimab) for people with advanced melanoma that cannot be removed by surgery or has spread. These drugs help your immune system fight the cancer more effectively.
This trial studies whether an individualized “neoantigen” cancer vaccine given to immune cells (dendritic cells) plus nivolumab can improve outcomes in people with liver cancer and/or colorectal cancer that has spread only to the liver. It focuses on tumors that can be removed with curative surgery (with or without local ablation) and on people with good enough liver and overall health.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
This trial tests a combination of three immunotherapy drugs (relatlimab, nivolumab, and ipilimumab) for people with melanoma that has spread to the brain. It aims to see if this treatment can shrink brain tumors and improve outcomes.
This trial tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) can clear tiny amounts of cancer cells that remain after surgery in people with high-risk melanoma. It aims to prevent the cancer from coming back.
Hear when a new Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.